Stomach cancer is a malignant tumor with a relatively high mortality rate. It ranks second and third in the mortality rate of all malignant tumors. According to clinical data, the survival rate of patients with advanced gastric cancer is relatively low, often less than 10% or even less than 5%; the median survival period of patients is also relatively short, which may be 6-9 months. However, with active treatment, the survival quality of patients with advanced gastric cancer can be continuously improved. For example, it can be combined with chemotherapy, radiotherapy and molecular targeted therapy, and even with immunotherapy, which can significantly extend the survival time of patients.